TRAW Valuation

Traws Pharma Inc

Add to Watchlist

Advanced Chart

1.580

-0.05(-3.067%)1D

Overview
Forecast
Valuation
Earnings

TRAW Relative Valuation

TRAW's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TRAW is overvalued; if below, it's undervalued.

Historical Valuation

Traws Pharma Inc (TRAW) is now in the Fair zone, suggesting that its current forward PS ratio of 39.43 is considered Fairly compared with the five-year average of -12.78. The fair price of Traws Pharma Inc (TRAW) is between 1.09 to 2.72 according to relative valuation methord.

Relative Value

Fair Zone

1.09-2.72

Current Price：1.58

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.47

P/B

Median3y

-0.25

Median5y

2.29

-339.64

FCF Yield

Median3y

-152.12

Median5y

-104.99

Competitors Valuation Multiple

The average P/S ratio for TRAW's competitors is 20.13, providing a benchmark for relative valuation. Traws Pharma Inc Corp (TRAW) exhibits a P/S ratio of 39.43, which is 95.90% above the industry average. Given its robust revenue growth of 1.79%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap